Results of a randomized clinical trial in Spain shows that reduced intensity, bortezomib-based (Velcade) induction therapy, followed by bortezomib-based maintenance therapy, results in a favorable toxicity profile and high efficacy among older patients. Go to OncologySTATS’ site to read the study.
I saw results from a similar study in the U.S. at ASCO in Chicago this past June. Nice to know researchers in other countries are working to help us too!
Feel good and keep smiling! Pat